Kiora Pharmaceuticals Advances KIO-401 IND Pathway

Regulatory affairs teams managing global development programs should note how Kiora Pharmaceuticals is structuring its U.S. entry for KIO-401 (mitucapistat): a Type B pre-IND meeting request submitted to FDA, with the asset arriving already backed by Phase 2 and Phase 3 data generated in Japan under Senju Pharmaceutical. The approach places existing foreign clinical data at the center of an IND strategy for a condition, central retinal artery occlusion (CRAO), that currently has no approved pharmacologic treatment.

Kiora in-licensed exclusive development and commercialization rights outside Asia from Senju Pharmaceutical Co., Ltd., acquiring an oral calpain inhibitor with an established CMC, non-clinical, and clinical data package. The pre-IND engagement is intended to align FDA on the IND pathway, trial design, and approvable endpoints before Kiora initiates a multinational Phase 3 registration trial spanning the United States, Europe, and additional territories. A request for orphan drug designation for KIO-401 in CRAO has also been submitted; if granted, it would confer development incentives and eligibility for post-approval market exclusivity under 21 CFR Part 316.

For regulatory leads, the strategic read here centers on bridging foreign Phase 3 data to an FDA-acceptable registration pathway. Japan-sourced efficacy data can support an IND and inform endpoint selection, but FDA alignment on what constitutes an approvable primary endpoint in an acute ischemic ophthalmic event will be the critical variable the pre-IND meeting is designed to resolve. Kiora's concurrent orphan designation request adds a procedural layer that, if successful, shapes the trial's statistical and commercial architecture before a single U.S. patient is enrolled.

On the operational side, Kiora appointed Keith Lane, MBA, formerly Chief Scientific Officer at Ora, Inc., as EVP of Clinical Development and Regulatory Affairs. Lane brings oversight experience across more than 100 clinical trials, including more than 10 global pivotal Phase 3 ophthalmic studies, a profile directly relevant to executing a multinational registration program. The company also reported a cash position of approximately $16.3 million in cash and short-term investments at September 30, 2026, alongside $2.2 million in collaboration, tax, and other receivables.

Separately, the KIO-301 ABACUS-2 trial continues enrolling and dosing patients at the 100 μg cohort level, and Kiora out-licensed KIO-301 development and commercial rights in South Korea to Chong Kun Dang Pharmaceutical Corporation, extending its regional network while concentrating internal resources on the KIO-401 program.

The outcome of the Type B pre-IND meeting with FDA will determine the endpoint framework and trial design parameters that Kiora carries into its planned multinational Phase 3 registration study for KIO-401.

Source: Kiora Pharmaceuticals, Inc. via ir.kiorapharma.com, November 12, 2026.